Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients

Y. Wang; T. K. Choueiri; J. L. Lee; M. H. Tan; S. Y. Rha; S. A. North; C. K. Kollmannsberger; D. F. McDermott; D. Y.C. Heng

doi:10.1038/bjc.2014.28

Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients

Y. Wang, T. K. Choueiri, J. L. Lee, M. H. Tan, S. Y. Rha, S. A. North, C. K. Kollmannsberger, D. F. McDermott, D. Y.C. Heng

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. Methods: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose reductions and outcomes using the International mRCC Database Consortium. Results: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of dose modifications/reductions between non-Asians and Asians was similar (55% vs 61% P=0.1197). When adjusted for risk groups, there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months, P<0.0001; 22.6 vs 16.1 months, P=0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P=0.0028; 28.0 vs 18.7 months, P=0.0069, respectively). Conclusions: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to longer treatment durations, but direct comparisons are needed.

Original language	English
Pages (from-to)	1433-1437
Number of pages	5
Journal	British journal of cancer
Volume	110
Issue number	6
DOIs	https://doi.org/10.1038/bjc.2014.28
Publication status	Published - 2014 Mar 18

Bibliographical note

Funding Information:
TKC has received research funding from Pfizer and has an advisory role at Aveo, Pfizer, Novartis, GlaxoSmithKline, Genentech, Bayer, and Onyx. CK has an advisory role at Pfizer, Novartis, and GlaxoSmithKline and has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. J-LL has received honoraria from Bayer, Pfizer, GSK, Janssen and research funding from Bayer. DYCH has an advisory role at Aveo, Pfizer, Novartis, and Bayer. YW, SAN, M-HT, S-YR, and DFM declare that they have no conflicts of interest.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2014.28

Cite this

@article{6bcd50c03b2c44c8a12f081d5bcb04c3,

title = "Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients",

abstract = "Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. Methods: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose reductions and outcomes using the International mRCC Database Consortium. Results: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of dose modifications/reductions between non-Asians and Asians was similar (55% vs 61% P=0.1197). When adjusted for risk groups, there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months, P<0.0001; 22.6 vs 16.1 months, P=0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P=0.0028; 28.0 vs 18.7 months, P=0.0069, respectively). Conclusions: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to longer treatment durations, but direct comparisons are needed.",

author = "Y. Wang and Choueiri, {T. K.} and Lee, {J. L.} and Tan, {M. H.} and Rha, {S. Y.} and North, {S. A.} and Kollmannsberger, {C. K.} and McDermott, {D. F.} and Heng, {D. Y.C.}",

note = "Funding Information: TKC has received research funding from Pfizer and has an advisory role at Aveo, Pfizer, Novartis, GlaxoSmithKline, Genentech, Bayer, and Onyx. CK has an advisory role at Pfizer, Novartis, and GlaxoSmithKline and has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. J-LL has received honoraria from Bayer, Pfizer, GSK, Janssen and research funding from Bayer. DYCH has an advisory role at Aveo, Pfizer, Novartis, and Bayer. YW, SAN, M-HT, S-YR, and DFM declare that they have no conflicts of interest.",

year = "2014",

month = mar,

day = "18",

doi = "10.1038/bjc.2014.28",

language = "English",

volume = "110",

pages = "1433--1437",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Anti-VEGF therapy in mRCC

T2 - Differences between Asian and non-Asian patients

AU - Wang, Y.

AU - Choueiri, T. K.

AU - Lee, J. L.

AU - Tan, M. H.

AU - Rha, S. Y.

AU - North, S. A.

AU - Kollmannsberger, C. K.

AU - McDermott, D. F.

AU - Heng, D. Y.C.

N1 - Funding Information: TKC has received research funding from Pfizer and has an advisory role at Aveo, Pfizer, Novartis, GlaxoSmithKline, Genentech, Bayer, and Onyx. CK has an advisory role at Pfizer, Novartis, and GlaxoSmithKline and has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. J-LL has received honoraria from Bayer, Pfizer, GSK, Janssen and research funding from Bayer. DYCH has an advisory role at Aveo, Pfizer, Novartis, and Bayer. YW, SAN, M-HT, S-YR, and DFM declare that they have no conflicts of interest.

PY - 2014/3/18

Y1 - 2014/3/18

N2 - Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. Methods: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose reductions and outcomes using the International mRCC Database Consortium. Results: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of dose modifications/reductions between non-Asians and Asians was similar (55% vs 61% P=0.1197). When adjusted for risk groups, there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months, P<0.0001; 22.6 vs 16.1 months, P=0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P=0.0028; 28.0 vs 18.7 months, P=0.0069, respectively). Conclusions: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to longer treatment durations, but direct comparisons are needed.

AB - Background: Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these agents with respect to ethnicity is not well characterised. Methods: A multicentre, retrospective, cohort study using Asian and non-Asian centres which collected data on ethnicity, dose reductions and outcomes using the International mRCC Database Consortium. Results: This study included 1024 (464 Asian, 560 non-Asian) patients with a 29.4 months median follow-up. The percentage of dose modifications/reductions between non-Asians and Asians was similar (55% vs 61% P=0.1197). When adjusted for risk groups, there was no difference in overall or progression-free survival between non-Asians and Asians. Patients with dose reductions due to toxicity had longer treatment durations and overall survival than those who did not in both non-Asian (10.6 vs 5.0 months, P<0.0001; 22.6 vs 16.1 months, P=0.0016, respectively) and Asian populations (8.9 vs 5.4 months, P=0.0028; 28.0 vs 18.7 months, P=0.0069, respectively). Conclusions: Adjusting for risk groups, there appears to be no difference in outcome between Asian vs non-Asian patients with mRCC treated with VEGF-targeted therapy. Judicious dose reductions may allow for better outcomes in both populations due to longer treatment durations, but direct comparisons are needed.

UR - http://www.scopus.com/inward/record.url?scp=84896494305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896494305&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.28

DO - 10.1038/bjc.2014.28

M3 - Article

C2 - 24548864

AN - SCOPUS:84896494305

VL - 110

SP - 1433

EP - 1437

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -

Anti-VEGF therapy in mRCC: Differences between Asian and non-Asian patients

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this